Jula K Inrig
Overview
Explore the profile of Jula K Inrig including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
1267
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Inrig J, Molina C, DSilva K, Kim C, Van Buren P, Allen J, et al.
Am J Kidney Dis
. 2014 Dec;
65(3):464-73.
PMID: 25530107
Background: Intradialytic hypertension affects ∼15% of hemodialysis patients and is associated with increased morbidity and mortality. While intradialytic hypertension is associated with increases in endothelin 1 relative to nitric oxide...
12.
Inrig J, Califf R, Tasneem A, Vegunta R, Molina C, Stanifer J, et al.
Am J Kidney Dis
. 2013 Dec;
63(5):771-80.
PMID: 24315119
Background: Well-designed trials are of paramount importance in improving the delivery of care to patients with kidney disease. However, it remains unknown whether contemporary clinical trials within nephrology are of...
13.
Inrig J
Kidney Int
. 2013 Oct;
84(4):641-4.
PMID: 24080873
Park et al. performed a retrospective analysis of a large hemodialysis cohort to describe the relationship between pre- to postdialysis changes in BP and mortality. Their study demonstrated adverse outcomes...
14.
McCullough P, Barnhart H, Inrig J, Reddan D, Sapp S, Patel U, et al.
Am J Nephrol
. 2013 Jun;
37(6):549-58.
PMID: 23735819
Background: Recombinant erythropoietin has become a routine component of care of patients with chronic kidney disease reducing the need for blood transfusions but raising the risks for cardiovascular events. We...
15.
Flythe J, Inrig J, Shafi T, Chang T, Cape K, Dinesh K, et al.
Am J Kidney Dis
. 2013 Mar;
61(6):966-74.
PMID: 23474007
Background: Blood pressure is known to fluctuate widely during hemodialysis; however, little is known about the association between intradialytic blood pressure variability and outcomes. Study Design: Retrospective observational cohort. Setting...
16.
Van Buren P, Kim C, Toto R, Inrig J
Int J Artif Organs
. 2012 Oct;
35(12):1031-8.
PMID: 23065874
Background: Intradialytic hypertension, a phenomenon where blood pressure increases during hemodialysis, is associated with increased mortality in hemodialysis patients. The proportion of patients in which intradialytic hypertension persists over time...
17.
Inrig J, Van Buren P, Kim C, Vongpatanasin W, Povsic T, Toto R
Clin J Am Soc Nephrol
. 2012 Jun;
7(8):1300-9.
PMID: 22700888
Background And Objectives: Intradialytic hypertension may be caused by an impaired endothelial cell response to hemodialysis. Carvedilol has been shown to improve endothelial cell function in vivo and to block...
18.
Inrig J, Sapp S, Barnhart H, Patel U, Reddan D, Singh A, et al.
Nephrol Dial Transplant
. 2012 May;
27(9):3606-14.
PMID: 22573238
Background: Targeting a higher hemoglobin in patients with chronic kidney disease leads to adverse cardiovascular outcomes, yet the reasons remain unclear. Herein, we sought to determine whether changes in erythropoiesis-stimulating...
19.
Inrig J, Barnhart H, Reddan D, Patel U, Sapp S, Califf R, et al.
Am J Kidney Dis
. 2012 Apr;
60(3):390-401.
PMID: 22537421
Background: Conflicting relationships have been described between anemia correction using erythropoiesis-stimulating agents and progression of chronic kidney disease (CKD). This study was undertaken to examine the impact of target hemoglobin...
20.
Van Buren P, Shastri S, Inrig J
Am J Kidney Dis
. 2012 Feb;
59(3):333-5.
PMID: 22340909
No abstract available.